Previous 10 | Next 10 |
Investors rewarded Neurocrine Biosciences (NASDAQ: NBIX) on Wednesday for posting a Q1 of fiscal 2020 earnings report that featured encouraging growth in key financials. The biotech company published the quarterly release after market hours on Tuesday, revealing that it booked...
Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q1 2020 Earnings Call May 6, 2020 , 6:30 p.m. ET Operator Continue reading
In a year that was always going to be relatively weak for stock-moving catalysts, Neurocrine Biosciences ( NBIX ) is at least hitting the mark with respect to execution. Not only did Ingrezza once again come in ahead of expectations, but the company is doing what it can to prepare to advance...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new data from RE-KINECT, the largest ever real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD) demonstrating that the inv...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Neurocrine Bioscineces, Inc. (NBIX) Q1 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Kevin Gorman – Chief Executive Officer Todd Tushla – Head-Investor Relations Matt Abernethy – Chief Financial Officer Eric Benevich – Chi...
Neurocrine Biosciences (NASDAQ: NBIX ): Q1 Non-GAAP EPS of $0.82 beats by $0.23 ; GAAP EPS of $0.39 misses by $0.15 . Revenue of $237.1M (+71.3% Y/Y) beats by $10.81M . Press Release More news on: Neurocrine Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2020 and provided revised full-year 2020 financial expense guidance. "First and foremost, I would like to t...
Neurocrine Biosciences ( NBIX ) is a biopharma company focused on treating CNS and endocrine disorders. Neurocrine has been cash flow positive for the last 2 years off the back of strong sales of Ingrezza, a soon-to-be blockbuster used to treat tardive dyskinesia. Rather than resting on its ...
Neurocrine Biosciences (NASDAQ: NBIX ) is scheduled to announce Q1 earnings results on Wednesday, May 6th, after market close. The consensus EPS Estimate is $0.59 (+152.7% Y/Y) and the consensus Revenue Estimate is $226.29M (+63.5% Y/Y). Over the last 2 years, NBIX has beaten EPS esti...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...